Saba Capital Management Amends abrdn Life Sciences Investors Filing
Ticker: HQL · Form: SC 13D/A · Filed: Apr 29, 2024 · CIK: 884121
| Field | Detail |
|---|---|
| Company | Abrdn Life Sciences Investors (HQL) |
| Form Type | SC 13D/A |
| Filed Date | Apr 29, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01, $39,527,455 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 13D-filing, amendment, activism
TL;DR
Saba Capital updated its abrdn Life Sciences stake filing - 4th amendment.
AI Summary
Saba Capital Management, L.P. has amended its Schedule 13D filing regarding abrdn Life Sciences Investors, as of April 29, 2024. The filing indicates changes in beneficial ownership, though specific new holdings or dollar amounts are not detailed in this excerpt. This amendment is the fourth such filing by Saba Capital Management.
Why It Matters
Changes in significant shareholder filings like this can signal shifts in investment strategy or potential activism, impacting the stock's performance and corporate governance.
Risk Assessment
Risk Level: medium — Amendments to 13D filings often indicate active investment strategies or potential changes in control, which can introduce volatility.
Key Numbers
- 4 — Amendment Number (This is the fourth amendment to the filing.)
Key Players & Entities
- Saba Capital Management, L.P. (company) — Filing entity
- abrdn Life Sciences Investors (company) — Subject company
- BOAZ R. WEINSTEIN (person) — Group member of Saba Capital Management
- SABA CAPITAL MANAGEMENT GP, LLC (company) — Group member of Saba Capital Management
FAQ
What specific changes in beneficial ownership are detailed in this Amendment No. 4 filing?
This excerpt does not specify the exact changes in beneficial ownership, only that the filing is an amendment.
What is the filing date of this Schedule 13D/A?
The filing date is April 29, 2024.
Who is the subject company of this filing?
The subject company is abrdn Life Sciences Investors.
Who is the entity filing this Schedule 13D/A?
The entity filing is Saba Capital Management, L.P.
What is the CUSIP number for abrdn Life Sciences Investors' Common Shares?
The CUSIP number is 87911K100.
Filing Stats: 1,329 words · 5 min read · ~4 pages · Grade level 11.6 · Accepted 2024-04-29 10:52:45
Key Financial Figures
- $0.01 — tors (Name of Issuer) Common Shares, $0.01 par value (Title of Class of Securiti
- $39,527,455 — ported herein. A total of approximately $39,527,455 was paid to acquire the Common Shares r
Filing Documents
- formsc13da.htm (SC 13D/A) — 64KB
- 0001062993-24-008941.txt ( ) — 65KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: April 29, 2024 SABA CAPITAL MANAGEMENT, L.P. By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Chief Compliance Officer SABA CAPITAL MANAGEMENT GP, LLC By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Authorized Signatory BOAZ R. WEINSTEIN By: /s/ Michael D'Angelo Name: Michael D'Angelo Title: Attorney-in-fact* * Pursuant to a power of attorney dated as of November 16, 2015, which is incorporated herein by reference to Exhibit 2 to the Schedule 13G filed by the Reporting Persons on December 28, 2015, accession number: 0001062993-15-006823 CUSIP No. 87911K100 SCHEDULE 13D/A Page 7 of 7 Pages Schedule A This Schedule sets forth information with respect to each purchase and sale of Common Shares which were effectuated by Saba Capital since the filing of the Schedule 13D/A on 4/17/24. All transactions were effectuated in the open market through a broker. Trade Date Buy/Sell Shares Price 4/18/2024 Buy 81,738 12.80 4/19/2024 Buy 15,000 12.84 4/19/2024 Buy 27,459 12.83 4/22/2024 Buy 2,022 12.88 4/23/2024 Buy 48,203 13.15 4/24/2024 Buy 20,529 13.12 4/25/2024 Buy 97,574 12.99 4/26/2024 Buy 120,304 13.00